A Phase 3, Randomized, Multicenter, Open-Label, Parallel-Group
Clinical Study Comparing the Safety and Efficacy of MYL-1601D with
NovoLog in Type 1 Diabetes Mellitus Patients (Protocol
MYL-1601D-3001)
Please contact us for more information or to learn if you are eligible to participate.
